Drug News

July 2011 
Volume 41  Number 7
Pages 18 - 18
  PDF Version Available!

Linagliptin (Tradjenta), a dipeptidyl peptidase-4 inhibitor, has been approved by the FDA as an adjunct to diet and exercise to help improve glycemic control in adults with type 2 diabetes. Linagliptin was tested in eight double-blind, placebo-controlled studies involving about 3,800 patients with type 2 diabetes. The studies showed improved glycemic control when linagliptin was used as monotherapy and in combination with drugs such as metformin, glimepiride, and pioglitazone.Common adverse reactions to linagliptin include upper respiratory infection, rhinitis, nasopharyngitis, myalgia, and headache. The drug shouldn't be used in patients with type 1 diabetes or those with diabetic ketoacidosis.Source: U.S. Food and Drug Administration. FDA approves new treatment for type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.htm .The FDA released final guidance to drug companies that manufacture, market, or distribute over-the-counter (OTC) liquid medications

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events